FR2825154B1 - Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique - Google Patents

Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique

Info

Publication number
FR2825154B1
FR2825154B1 FR0106754A FR0106754A FR2825154B1 FR 2825154 B1 FR2825154 B1 FR 2825154B1 FR 0106754 A FR0106754 A FR 0106754A FR 0106754 A FR0106754 A FR 0106754A FR 2825154 B1 FR2825154 B1 FR 2825154B1
Authority
FR
France
Prior art keywords
stimulating
production
compounds capable
antibody
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0106754A
Other languages
English (en)
Other versions
FR2825154A1 (fr
Inventor
Alain Friboulet
Bihan Berangere Avalle
Helene Debat
Daniel Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Technologie de Compiegne
Universite de Technologie de Compiegne UTC
Original Assignee
Universite de Technologie de Compiegne
Universite de Technologie de Compiegne UTC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0106754A priority Critical patent/FR2825154B1/fr
Application filed by Universite de Technologie de Compiegne, Universite de Technologie de Compiegne UTC filed Critical Universite de Technologie de Compiegne
Priority to MXPA03010694A priority patent/MXPA03010694A/es
Priority to EP02732880A priority patent/EP1390478A1/fr
Priority to BR0209934-9A priority patent/BR0209934A/pt
Priority to JP2002592478A priority patent/JP2004527579A/ja
Priority to TNPCT/FR2002/001730A priority patent/TNSN03120A1/fr
Priority to PCT/FR2002/001730 priority patent/WO2002095015A1/fr
Priority to AU2002304489A priority patent/AU2002304489B2/en
Priority to CA2448174A priority patent/CA2448174C/fr
Publication of FR2825154A1 publication Critical patent/FR2825154A1/fr
Priority to US10/716,030 priority patent/US7109291B2/en
Application granted granted Critical
Publication of FR2825154B1 publication Critical patent/FR2825154B1/fr
Priority to AU2009202300A priority patent/AU2009202300A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/901—Antibodies with enzymatic activity; e.g. abzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
FR0106754A 2001-05-22 2001-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique Expired - Fee Related FR2825154B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0106754A FR2825154B1 (fr) 2001-05-22 2001-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
CA2448174A CA2448174C (fr) 2001-05-22 2002-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
BR0209934-9A BR0209934A (pt) 2001-05-22 2002-05-22 Composto, utilização de um composto, processo de seleção de um composto, e composição farmacêutica.
JP2002592478A JP2004527579A (ja) 2001-05-22 2002-05-22 触媒抗体の活性を調整し、且つその産生を刺激することが可能な化合物
TNPCT/FR2002/001730A TNSN03120A1 (fr) 2001-05-22 2002-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
PCT/FR2002/001730 WO2002095015A1 (fr) 2001-05-22 2002-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
MXPA03010694A MXPA03010694A (es) 2001-05-22 2002-05-22 Compuestos capaqces de modular la actividad y estimular la produccion de un anticuerpo catalitico.
EP02732880A EP1390478A1 (fr) 2001-05-22 2002-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
AU2002304489A AU2002304489B2 (en) 2001-05-22 2002-05-22 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
US10/716,030 US7109291B2 (en) 2001-05-22 2003-11-17 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
AU2009202300A AU2009202300A1 (en) 2001-05-22 2009-06-10 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0106754A FR2825154B1 (fr) 2001-05-22 2001-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique

Publications (2)

Publication Number Publication Date
FR2825154A1 FR2825154A1 (fr) 2002-11-29
FR2825154B1 true FR2825154B1 (fr) 2004-01-30

Family

ID=8863562

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0106754A Expired - Fee Related FR2825154B1 (fr) 2001-05-22 2001-05-22 Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique

Country Status (10)

Country Link
US (1) US7109291B2 (fr)
EP (1) EP1390478A1 (fr)
JP (1) JP2004527579A (fr)
AU (2) AU2002304489B2 (fr)
BR (1) BR0209934A (fr)
CA (1) CA2448174C (fr)
FR (1) FR2825154B1 (fr)
MX (1) MXPA03010694A (fr)
TN (1) TNSN03120A1 (fr)
WO (1) WO2002095015A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011639A2 (fr) * 2005-07-13 2007-01-25 Coimmune Inc. Immunoglobulines catalytiques
UA105278C2 (ru) * 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504906A (en) * 1982-11-30 1985-03-12 Anritsu Electric Company Limited Multiprocessor system
US5349690A (en) * 1988-05-11 1994-09-20 Digital Equipment Corporation Fair arbitration scheme for arbitrating between multiple nodes in a computer system seeking control of a common bus
DE3841767A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
WO1996034887A2 (fr) * 1995-05-05 1996-11-07 Imperial College Of Science, Technology & Medicine Peptides anti-sens
US5948658A (en) * 1996-06-25 1999-09-07 The Trustees Of Columbia University In The City Of New York Anti-cocaine catalytic antibody
US6235714B1 (en) * 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
US6560712B1 (en) * 1999-11-16 2003-05-06 Motorola, Inc. Bus arbitration in low power system

Also Published As

Publication number Publication date
CA2448174C (fr) 2015-04-21
MXPA03010694A (es) 2005-03-07
EP1390478A1 (fr) 2004-02-25
US7109291B2 (en) 2006-09-19
FR2825154A1 (fr) 2002-11-29
BR0209934A (pt) 2004-04-06
AU2009202300A1 (en) 2009-07-02
AU2002304489B2 (en) 2009-07-02
WO2002095015A1 (fr) 2002-11-28
TNSN03120A1 (fr) 2005-12-23
JP2004527579A (ja) 2004-09-09
CA2448174A1 (fr) 2002-11-28
US20040138124A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
TR200201094T2 (tr) Farmasötik maddeler olarak bisiklik amino asitler
ATE424219T1 (de) Hemmende antikörper der her3-aktivität
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
DE60237768D1 (de) Modulatoren pharmakologischer mittel
NL300382I1 (nl) Treatment of pompe's disease
CY1108566T1 (el) Ανοσολογικος ελεγχος των επιπεδων του b-αμυλοειδους in vivo
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
DK0975595T3 (da) Kokainanaloger
HK1044477B (zh) 治療糖尿病的藥物
ATE355288T1 (de) Verbindungen und therapeutische methoden
SE0102147D0 (sv) New methods
HUP0105281A2 (hu) Rákellenes hatású benzaldehidszármazékok és gyógyászati alkalmazásuk
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
FR2825154B1 (fr) Composes capables de moduler l'activite et de stimuler la production d'un anticorps catalytique
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
EP1595536A4 (fr) Preparations pharmaceutiques dont la shikonine est le principe actif
ATE312626T1 (de) Mucoadhäsive, wärmeaktivierbare zubereitung als träger für medikamente
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
FR2821080B1 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE247984T1 (de) Bioreduktive konjugate zur gezielten wirkstoffzufuhr
WO2002062944A2 (fr) Nouveau peptide physiologiquement actif et son utilisation
ATE258229T1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
BR0113814A (pt) Amidas de ácido fenilciclohexanocarboxìlico e sua aplicação

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20180131